JP2023525049A5 - - Google Patents
Info
- Publication number
- JP2023525049A5 JP2023525049A5 JP2022567529A JP2022567529A JP2023525049A5 JP 2023525049 A5 JP2023525049 A5 JP 2023525049A5 JP 2022567529 A JP2022567529 A JP 2022567529A JP 2022567529 A JP2022567529 A JP 2022567529A JP 2023525049 A5 JP2023525049 A5 JP 2023525049A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- domain
- car
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022149P | 2020-05-08 | 2020-05-08 | |
| US63/022,149 | 2020-05-08 | ||
| PCT/US2021/031421 WO2021226543A2 (en) | 2020-05-08 | 2021-05-07 | Chimeric antigen receptors (cars) targeting natural killer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525049A JP2023525049A (ja) | 2023-06-14 |
| JP2023525049A5 true JP2023525049A5 (enExample) | 2024-05-16 |
Family
ID=78468790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567529A Pending JP2023525049A (ja) | 2020-05-08 | 2021-05-07 | ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230348854A1 (enExample) |
| EP (1) | EP4146703A4 (enExample) |
| JP (1) | JP2023525049A (enExample) |
| KR (1) | KR20230010228A (enExample) |
| CN (1) | CN115551893A (enExample) |
| WO (1) | WO2021226543A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021249462A1 (zh) * | 2020-06-11 | 2021-12-16 | 南京北恒生物科技有限公司 | 表达nk抑制性分子的工程化免疫细胞及其用途 |
| US11802866B2 (en) * | 2021-07-08 | 2023-10-31 | Medic Life Sciences Inc. | High-throughput screening system for identification of novel drugs and drug targets |
| EP4569117A2 (en) * | 2022-08-11 | 2025-06-18 | The Trustees of The University of Pennsylvania | Universal t cells and compositions and methods of use thereof |
| JP2025005236A (ja) * | 2023-06-27 | 2025-01-16 | 国立大学法人 東京大学 | タンパク質シンチレーター |
| WO2025168691A1 (en) * | 2024-02-07 | 2025-08-14 | Astrazeneca Ab | Engineered cells expressing modified hla-e polypeptide |
| CN120647771A (zh) * | 2024-03-15 | 2025-09-16 | 上海鑫湾生物科技有限公司 | 一种激活免疫细胞杀伤肿瘤细胞的融合蛋白及其重组病毒和用途 |
| WO2025225645A1 (ja) * | 2024-04-24 | 2025-10-30 | 第一三共株式会社 | Ｎｋｇ２ａアゴニストを用いた免疫拒絶の回避方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194548B1 (en) * | 1998-01-23 | 2001-02-27 | Takashi Osumi | Green fluorescent proteins and blue fluorescent proteins |
| AU2008204433B2 (en) * | 2007-01-11 | 2014-03-13 | Novo Nordisk A/S | Anti-KIR antibodies, formulations, and uses thereof |
| MX2010007935A (es) * | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| DK2699593T4 (da) * | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2015316993B2 (en) * | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| KR20250007689A (ko) * | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| CN107429253B (zh) * | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| EP3325967B1 (en) * | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| US10222369B2 (en) * | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| KR102708285B1 (ko) * | 2017-03-13 | 2024-09-20 | 포세이다 테라퓨틱스, 인크. | 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법 |
| JP2020536531A (ja) * | 2017-09-26 | 2020-12-17 | ロングウッド ユニバーシティーＬｏｎｇｗｏｏｄ Ｕｎｉｖｅｒｓｉｔｙ | 免疫療法としてのｐｄ１特異的キメラ抗原受容体 |
| IL315737A (en) * | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN109694854B (zh) * | 2017-10-20 | 2023-11-21 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| US11851679B2 (en) * | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| WO2019129851A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| US12473345B2 (en) * | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN109734814A (zh) * | 2019-02-12 | 2019-05-10 | 南京卡提医学科技有限公司 | 具有免疫受体的工程化t细胞治疗癌症的用途 |
| EP4150058A4 (en) * | 2020-05-13 | 2024-06-19 | Nanjing Legend Biotech Co., Ltd. | COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF |
-
2021
- 2021-05-07 JP JP2022567529A patent/JP2023525049A/ja active Pending
- 2021-05-07 KR KR1020227043093A patent/KR20230010228A/ko active Pending
- 2021-05-07 CN CN202180033601.0A patent/CN115551893A/zh active Pending
- 2021-05-07 EP EP21800939.7A patent/EP4146703A4/en active Pending
- 2021-05-07 WO PCT/US2021/031421 patent/WO2021226543A2/en not_active Ceased
- 2021-05-07 US US17/998,206 patent/US20230348854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028648A5 (enExample) | ||
| JP2022542543A5 (enExample) | ||
| RU2020124623A (ru) | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон | |
| TWI841790B (zh) | 靶向cd3的抗體、雙特異性抗體及其用途 | |
| JP2020530762A5 (enExample) | ||
| JP2017537925A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2017537629A5 (enExample) | ||
| JP2019513394A5 (enExample) | ||
| CN121427832A (zh) | 细胞 | |
| JP2019500848A5 (enExample) | ||
| HRP20160857T4 (hr) | Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene | |
| JP2015513920A5 (enExample) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| CN112940123B (zh) | 抗人程序性死亡受体1抗体及其制备方法和用途 | |
| JP2014502262A (ja) | Ｈｉｖ治療用の融合タンパク質 | |
| JP2021521793A5 (enExample) | ||
| JP2022542559A5 (enExample) | ||
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| JP2023519099A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| JP2022513682A5 (enExample) | ||
| JP2025508343A5 (enExample) | ||
| KR20230040333A (ko) | 다중특이성 키메라 항원 수용체 및 이의 용도 | |
| JP2024516713A5 (enExample) |